ibuprofen and Bilateral Headache studies

Research Excerpts

Excerpt	Relevance	Reference
"Our aim was to evaluate pain reduction provided by intranasal fentanyl (INF) compared with placebo in addition to ibuprofen."	9.69	Additive Value of Intranasal Fentanyl on Ibuprofen for Pain Management of Children With Moderate to Severe Headaches: A Randomized Controlled Trial. ( Bailey, B; Boutin, A; Gouin, S; Gravel, J; Lebel, D, 2023)
"Subjects in both the metoclopramide and ibuprofen arms reported reduced headache severity and nausea compared to pretreatment values at 120 min."	9.34	Prospective Double-Blinded Randomized Field-Based Clinical Trial of Metoclopramide and Ibuprofen for the Treatment of High Altitude Headache and Acute Mountain Sickness. ( Bhai, SF; Gregorie, WD; Harris, NS; Irons, HR; Salas, RN, 2020)
"The aim of this study is to determine the efficacy of preemptive analgesia with paracetamol and ibuprofen to reduce the intensity and incidence of headache and myalgia after electroconvulsive therapy (ECT)."	9.30	Effects of preemptive intravenous paracetamol and ibuprofen on headache and myalgia in patients after electroconvulsive therapy: A placebo-controlled, double-blind, randomized clinical trial. ( Akbas, S; Karaaslan, E; Ozkan, AS; Zayman, EP, 2019)
"To investigate short-term efficacy and safety of a novel lipid ibuprofen formulation 1200 mg/day compared with standard ibuprofen 1200 mg/day and 2400 mg/day in episodic knee arthralgia/flaring pain."	9.24	A new lipid formulation of low dose ibuprofen shows non-inferiority to high dose standard ibuprofen: the FLARE study (flaring arthralgia relief evaluation in episodic flaring knee pain) - a randomised double-blind study. ( Bierma-Zeinstra, SMA; Brew, J; Conaghan, PG; Kilbourn, A; Stoner, K; Wilson, R, 2017)
"Ibuprofen premedication reduced the frequency and severity of headache post-ECT and should be considered for appropriate patients who suffer from ECT-induced headache."	9.10	Pretreatment with ibuprofen to prevent electroconvulsive therapy-induced headache. ( Brown, GR; Hollander, Y; Leung, M, 2003)
"Ibuprofen has been shown to be more effective than placebo in the treatment of high altitude headache (HAH), but nonsteroidal anti-inflammatory agents have been linked to increased incidence of gastrointestinal (GI) side effects and high-altitude pulmonary edema (HAPE)."	9.10	High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. ( Harris, NS; Thomas, SH; Wenzel, RP, 2003)
" Single doses of ketoprofen 25 mg and ketoprofen 50 mg were compared with ibuprofen 200 mg and placebo in the treatment of a single occasion of episodic tension-type headache, using a double-blind, randomized, parallel group design."	9.08	Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. ( Cohen, AF; Hoedemaker, HG; Jacobs, LD; Ouwersloot-van der Meij, MJ; Reints, A; Schoemaker, RC; van Gerven, JM, 1996)
"Ibuprofen is used to prevent high altitude headache (HAH) but its efficacy remains controversial."	8.95	Efficacy of ibuprofen on prevention of high altitude headache: A systematic review and meta-analysis. ( Jia, Z; Lu, H; Wang, R; Xiong, J, 2017)
" The earlier review included 20 studies (7238 participants) in valid comparisons, but because we used different outcomes for some headache studies, the number of participants in the analyses of the effects of caffeine is now 4262 when previously it was 5243."	8.90	Caffeine as an analgesic adjuvant for acute pain in adults. ( Derry, CJ; Derry, S; Moore, RA, 2014)
" Most studies used paracetamol or ibuprofen, with 100 mg to 130 mg caffeine, and the most common pain conditions studied were postoperative dental pain, postpartum pain, and headache."	8.88	Caffeine as an analgesic adjuvant for acute pain in adults. ( Derry, CJ; Derry, S; Moore, RA, 2012)
"A simple, sensitive, and selective first derivative synchronous fluorimetric method was developed and optimized to track the influence of caffeine content in beverages on the pharmacokinetic parameters of three pharmaceuticals used in relieving headache namely, aspirin (ASP), ibuprofen (IBU), and ergotamine tartrate (ERG)."	8.12	Tracing the influence of caffeine on the pharmacokinetic parameters of three headache relieving pharmaceuticals applying synchronous fluorescence spectroscopy. ( Draz, ME; El Enany, N; El Sherbiny, D; Wahba, MEK, 2022)
"A healthy 15-year-old boy presented to the emergency department with headache, nausea, dizziness, fever, conjunctival hyperemia and blurred vision 30 minutes after ibuprofen-intake."	7.91	IBUPROFEN-INDUCED ASEPTIC MENINGITIS: A CASE REPORT. ( Agro, JPSEABD; Lemos, AP; Maia, PADSV; Pereira, EPMN; Pires, SAP, 2019)
" We present in this paper a case of ibuprofen anaphylaxis that exemplifies the challenges involved in diagnosis and management of hypersensitivity reactions to NSAIDs."	7.79	Anaphylaxis to ibuprofen in a 12-year-old boy. ( Ben-Shoshan, M; Kay, E, 2013)
"Ibuprofen was similar to acetazolamide in preventing symptoms of AMS, an interesting finding that implies a potentially new approach to prevention of cerebral forms of acute altitude illness."	6.75	Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). ( Allison, E; Basnyat, B; Fisher, RS; Gertsch, JH; Hanzelka, K; Hazan, A; Holck, PS; Lipman, GS; Merritt, A; Meyers, Z; Mulcahy, A; Odegaard, J; Pook, B; Slomovic, B; Thompson, M; Wahlberg, H; Weiss, EA; Wilshaw, V; Zafren, K, 2010)
"Ibuprofen was significantly superior to placebo both in reducing headache severity and in speed of relief (a mean difference of 94 min in time to no/minimal headache)."	6.67	High altitude headache: treatment with ibuprofen. ( Beeley, JM; Broome, JR; Hughes, AS; Milledge, JS; Stoneham, MD, 1994)
"Rhinogenic headache is frequently encountered in clinical practice."	6.61	Update on the pathophysiology and treatment of rhinogenic headache: focus on the ibuprofen/pseudoephedrine combination. ( Camaioni, A; Chiarugi, A, 2019)
" Additional studies are needed to assess the relationship between caffeine dosing and clinical benefits in patients with TTH and migraine."	6.55	Caffeine in the management of patients with headache. ( Diener, HC; Garas, SY; Lipton, RB; Patel, K; Robbins, MS, 2017)
"Our aim was to evaluate pain reduction provided by intranasal fentanyl (INF) compared with placebo in addition to ibuprofen."	5.69	Additive Value of Intranasal Fentanyl on Ibuprofen for Pain Management of Children With Moderate to Severe Headaches: A Randomized Controlled Trial. ( Bailey, B; Boutin, A; Gouin, S; Gravel, J; Lebel, D, 2023)
"Sodium valproate and ibuprofen are drugs with known efficacy in the treatment of headache associated with acute migraine attacks."	5.51	Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial. ( Akbas, I; Ceylan, M; Dogruyol, S; Gur, STA; Kocak, AO; Kocak, MB; Tekyol, D, 2022)
"Unlike other non-steroidal anti-inflammatory drugs, indomethacin has been shown to be highly effective in two forms of trigeminal autonomic cephalalgias, hemicrania continua and paroxysmal hemicrania and in some forms of idiopathic stabbing headaches."	5.51	Indomethacin has no effect on trigeminally provoked parasympathetic output. ( Iwersen-Bergmann, S; May, A; Mehnert, J; Möller, M; Schröder, C, 2022)
"Subjects in both the metoclopramide and ibuprofen arms reported reduced headache severity and nausea compared to pretreatment values at 120 min."	5.34	Prospective Double-Blinded Randomized Field-Based Clinical Trial of Metoclopramide and Ibuprofen for the Treatment of High Altitude Headache and Acute Mountain Sickness. ( Bhai, SF; Gregorie, WD; Harris, NS; Irons, HR; Salas, RN, 2020)
"The aim of this study is to determine the efficacy of preemptive analgesia with paracetamol and ibuprofen to reduce the intensity and incidence of headache and myalgia after electroconvulsive therapy (ECT)."	5.30	Effects of preemptive intravenous paracetamol and ibuprofen on headache and myalgia in patients after electroconvulsive therapy: A placebo-controlled, double-blind, randomized clinical trial. ( Akbas, S; Karaaslan, E; Ozkan, AS; Zayman, EP, 2019)
"To investigate short-term efficacy and safety of a novel lipid ibuprofen formulation 1200 mg/day compared with standard ibuprofen 1200 mg/day and 2400 mg/day in episodic knee arthralgia/flaring pain."	5.24	A new lipid formulation of low dose ibuprofen shows non-inferiority to high dose standard ibuprofen: the FLARE study (flaring arthralgia relief evaluation in episodic flaring knee pain) - a randomised double-blind study. ( Bierma-Zeinstra, SMA; Brew, J; Conaghan, PG; Kilbourn, A; Stoner, K; Wilson, R, 2017)
"Ibuprofen has been shown to be more effective than placebo in the treatment of high altitude headache (HAH), but nonsteroidal anti-inflammatory agents have been linked to increased incidence of gastrointestinal (GI) side effects and high-altitude pulmonary edema (HAPE)."	5.10	High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. ( Harris, NS; Thomas, SH; Wenzel, RP, 2003)
"Ibuprofen premedication reduced the frequency and severity of headache post-ECT and should be considered for appropriate patients who suffer from ECT-induced headache."	5.10	Pretreatment with ibuprofen to prevent electroconvulsive therapy-induced headache. ( Brown, GR; Hollander, Y; Leung, M, 2003)
" Single doses of ketoprofen 25 mg and ketoprofen 50 mg were compared with ibuprofen 200 mg and placebo in the treatment of a single occasion of episodic tension-type headache, using a double-blind, randomized, parallel group design."	5.08	Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. ( Cohen, AF; Hoedemaker, HG; Jacobs, LD; Ouwersloot-van der Meij, MJ; Reints, A; Schoemaker, RC; van Gerven, JM, 1996)
"Ibuprofen is used to prevent high altitude headache (HAH) but its efficacy remains controversial."	4.95	Efficacy of ibuprofen on prevention of high altitude headache: A systematic review and meta-analysis. ( Jia, Z; Lu, H; Wang, R; Xiong, J, 2017)
" The earlier review included 20 studies (7238 participants) in valid comparisons, but because we used different outcomes for some headache studies, the number of participants in the analyses of the effects of caffeine is now 4262 when previously it was 5243."	4.90	Caffeine as an analgesic adjuvant for acute pain in adults. ( Derry, CJ; Derry, S; Moore, RA, 2014)
" Most studies used paracetamol or ibuprofen, with 100 mg to 130 mg caffeine, and the most common pain conditions studied were postoperative dental pain, postpartum pain, and headache."	4.88	Caffeine as an analgesic adjuvant for acute pain in adults. ( Derry, CJ; Derry, S; Moore, RA, 2012)
" For the acute treatment of migraine attacks or tension-type headache, ibuprofen (10 mg per kg body weight) or acetaminophen (15 mg per kg body weight) are recommended with highest evidence, intranasal sumatriptan (10 to 20 mg) can be given as second choice."	4.81	[Treatment of idiopathic headache in childhood - recommendations of the German Migraine and Headache Society (DMKG)]. ( Evers, S; Gerber, WD; Naumann, E; Pothmann, R; Uberall, M, 2002)
"In the present population recruited at specialized headache centers, patients rated triptans as more effective than non-opioid analgesics, naproxen as more effective than ibuprofen, and acute medication efficacy decreased with increasing headache frequency."	4.31	What do patients' efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry. ( Dresler, T; Förderreuther, S; Gaul, C; Gossrau, G; Jürgens, TP; Ruscheweyh, R; Ruschil, V; Scheidt, J; Straube, A, 2023)
"A simple, sensitive, and selective first derivative synchronous fluorimetric method was developed and optimized to track the influence of caffeine content in beverages on the pharmacokinetic parameters of three pharmaceuticals used in relieving headache namely, aspirin (ASP), ibuprofen (IBU), and ergotamine tartrate (ERG)."	4.12	Tracing the influence of caffeine on the pharmacokinetic parameters of three headache relieving pharmaceuticals applying synchronous fluorescence spectroscopy. ( Draz, ME; El Enany, N; El Sherbiny, D; Wahba, MEK, 2022)
"This study investigates whether acute treatment with ibuprofen, acetaminophen, or both is associated with resolution of headache or reduction of headache pain at 7 days post-concussion in children and youth."	4.12	Early analgesic administration and headache presence 7 days post-concussion in children. ( Bell, MJ; Boutis, K; Freedman, SB; Gravel, J; Ledoux, A-; Mannix, RC; Richer, LR; Tang, K; Yeates, KO; Zemek, RL, 2022)
"Although neurological/ophthalmologic side effects including headache, vertigo, somnolence, paresthesia, optic neuritis, and optic neuropathy are listed as side effects in the medication guidelines for ibuprofen, transient tunnel vision and altered consciousness after a single dose of ibuprofen have not been reported."	4.12	Transient tunnel vision and altered consciousness after a single dose of ibuprofen. ( Finsterer, J, 2022)
"A healthy 15-year-old boy presented to the emergency department with headache, nausea, dizziness, fever, conjunctival hyperemia and blurred vision 30 minutes after ibuprofen-intake."	3.91	IBUPROFEN-INDUCED ASEPTIC MENINGITIS: A CASE REPORT. ( Agro, JPSEABD; Lemos, AP; Maia, PADSV; Pereira, EPMN; Pires, SAP, 2019)
" We present in this paper a case of ibuprofen anaphylaxis that exemplifies the challenges involved in diagnosis and management of hypersensitivity reactions to NSAIDs."	3.79	Anaphylaxis to ibuprofen in a 12-year-old boy. ( Ben-Shoshan, M; Kay, E, 2013)
"Three young women with systemic lupus erythematosus who were given ibuprofen for arthritis voluntarily discontinued taking the drug."	3.66	Acute adverse reactions to ibuprofen in systemic lupus erythematosus. ( Finch, WR; Strottman, MP, 1979)
"Ibuprofen was similar to acetazolamide in preventing symptoms of AMS, an interesting finding that implies a potentially new approach to prevention of cerebral forms of acute altitude illness."	2.75	Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). ( Allison, E; Basnyat, B; Fisher, RS; Gertsch, JH; Hanzelka, K; Hazan, A; Holck, PS; Lipman, GS; Merritt, A; Meyers, Z; Mulcahy, A; Odegaard, J; Pook, B; Slomovic, B; Thompson, M; Wahlberg, H; Weiss, EA; Wilshaw, V; Zafren, K, 2010)
" Ibuprofen arginate and dexibuprofen showed similar bioavailability for S(+)-ibuprofen."	2.72	A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers. ( Azanza, JR; Campanero, MA; Esteras, A; García-Quetglas, E; Gil-Aldea, I; Muñoz-Juarez, MJ; Sádaba, B, 2006)
"Diclofenac-K was superior to placebo (P < 0."	2.71	A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms. ( Frank, WO; Gold, MS; Grebe, W; Ionescu, E; Liu, JM, 2003)
"Ibuprofen is a peripherally acting nonsteroidal anti-inflammatory drug indicated fo ranalgesia, antipyresis, and various arthritic conditions."	2.70	Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain. ( Cooper, S; Doyle, G; Jayawardena, S; Marrero, I; Olson, NZ; Otero, AM; Sunshine, A; Tirado, S, 2001)
"Ibuprofen was significantly superior to placebo both in reducing headache severity and in speed of relief (a mean difference of 94 min in time to no/minimal headache)."	2.67	High altitude headache: treatment with ibuprofen. ( Beeley, JM; Broome, JR; Hughes, AS; Milledge, JS; Stoneham, MD, 1994)
"Rhinogenic headache is frequently encountered in clinical practice."	2.61	Update on the pathophysiology and treatment of rhinogenic headache: focus on the ibuprofen/pseudoephedrine combination. ( Camaioni, A; Chiarugi, A, 2019)
"Headache is an increasingly common symptom among children and adolescents with a prevalence of 58."	2.58	[Headache in children and adolescents]. ( Debes, NM; Gren, C; Miranda, M; Vogler, K, 2018)
" Additional studies are needed to assess the relationship between caffeine dosing and clinical benefits in patients with TTH and migraine."	2.55	Caffeine in the management of patients with headache. ( Diener, HC; Garas, SY; Lipton, RB; Patel, K; Robbins, MS, 2017)
"Ibuprofen (IBU) is an efficacious over-the-counter analgesic/antipyretic with adverse event (AE) rates comparable to placebo."	2.52	Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. ( Jayawardena, S; Kellstein, D; Leyva, R, 2015)
"Common types include sinusitis, migraine, and muscle contraction (tension)."	2.41	"Nurse, my head hurts": a review of childhood headaches. ( Fisher, W; Gordon, V; Kolar, KR, 2001)
"The most detailed posts on headache or migraine were from Germany."	1.91	Social Media Listening and Digital Profiling Study of People With Headache and Migraine: Retrospective Infodemiology Study. ( Amand, C; Constantin, L; Goadsby, P; Ruiz de la Torre, E, 2023)
"These drugs can be categorized into migraine-specific and migraine-non-specific."	1.72	2022 Taiwan Guidelines for Acute Treatment of Migraine. ( Lau, CI; Wang, YF, 2022)
"Fifty children, with 116 migraine attacks, were included in the study (30 females; mean age 12; range 6-18)."	1.72	Migraine abortive treatment in children and adolescents in Israel. ( Cohen, R; Genizi, J; Lahoud, D, 2022)
"Acupuncture is a promising method in treatment of headaches associated with meningeal sensitivity or irritation, such as migraine or post-dural puncture headache."	1.51	Treating Therapy-Resistant Headache After Aneurysmal Subarachnoid Hemorrhage with Acupuncture. ( Dietzel, J; Eck, T; Usichenko, T, 2019)
" The maximum steady-state drug concentration and area under the concentration curve from time 0 on day 5 (t = 0) to the 24-hours sample on day 6 were 514 ng/mL (95% CI 439 to 603 ng/mL) and 9."	1.48	A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers. ( Bhatt, A; Connolly, MP; Lewis, F, 2018)
"Childhood headache is a common condition."	1.36	[Update on current care guidelines; childhood headache]. ( , 2010)

Research

Studies (73)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Duration of Headache Free Period at 7 Days

Number of Participants With Development of Hypertensive Disease of Pregnancy Within 28 Days

Number of Participants With Development of Hypertensive Disease of Pregnancy Within 7 Days

Number of Participants With Injection Site Complication (Infection, Hematoma, and Ecchymosis)

Number of Participants With Need for Admission for Treatment of Headache

Number of Participants With Need for Crossover Treatment

Number of Participants With Need for Neurology Consult

Number of Participants With Need for Representation for Treatment of Headache With 28 Days

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (9.59)	18.7374
1990's	6 (8.22)	18.2507
2000's	18 (24.66)	29.6817
2010's	26 (35.62)	24.3611
2020's	16 (21.92)	2.80

Authors	Studies
Kazama, I	1
Senzaki, M	1
Dogruyol, S	1
Gur, STA	1
Akbas, I	1
Kocak, MB	1
Kocak, AO	1
Ceylan, M	1
Tekyol, D	1
Genizi, J	1
Lahoud, D	1
Cohen, R	1
Nelson, R	1
Kittel-Moseley, J	1
Mahoui, I	1
Thornberry, D	1
Dunkman, A	1
Sams, M	1
Adler, D	1
Jones, CMC	1
Wahba, MEK	1
El Sherbiny, D	1
El Enany, N	1
Draz, ME	1
Ledoux, A-	1
Tang, K	1
Freedman, SB	1
Gravel, J	2
Boutis, K	1
Yeates, KO	1
Mannix, RC	1
Richer, LR	1
Bell, MJ	1
Zemek, RL	1
Lau, CI	1
Wang, YF	1
Finsterer, J	1
Goadsby, P	1
Ruiz de la Torre, E	1
Constantin, L	1
Amand, C	1
Ruscheweyh, R	1
Dresler, T	1
Förderreuther, S	1
Gaul, C	1
Gossrau, G	1
Jürgens, TP	1
Ruschil, V	1
Straube, A	1
Scheidt, J	1
Boutin, A	1
Gouin, S	1
Bailey, B	2
Lebel, D	1
Karaaslan, E	1
Akbas, S	1
Ozkan, AS	1
Zayman, EP	1
Irons, HR	1
Salas, RN	1
Bhai, SF	1
Gregorie, WD	1
Harris, NS	2
MaassenVanDenBrink, A	1
de Vries, T	1
Danser, AHJ	1
Summ, O	1
Andreou, AP	1
Akerman, S	1
Holland, PR	1
Hoffmann, J	1
Goadsby, PJ	1
Toom, S	1
Wolf, B	1
Avula, A	1
Peeke, S	1
Becker, K	1
Möller, M	1
Schröder, C	1
Iwersen-Bergmann, S	1
Mehnert, J	1
May, A	1
Xiong, J	1
Lu, H	1
Wang, R	1
Jia, Z	1
Bierma-Zeinstra, SMA	1
Brew, J	1
Stoner, K	1
Wilson, R	1
Kilbourn, A	1
Conaghan, PG	1
Lipton, RB	1
Diener, HC	1
Robbins, MS	1
Garas, SY	1
Patel, K	1
Lewis, F	1
Connolly, MP	1
Bhatt, A	1
Gren, C	1
Vogler, K	1
Miranda, M	1
Debes, NM	1
Borchard-Tuch, C	1
Chiarugi, A	1
Camaioni, A	1
Dietzel, J	1
Eck, T	1
Usichenko, T	1
Pires, SAP	1
Lemos, AP	1
Pereira, EPMN	1
Maia, PADSV	1
Agro, JPSEABD	1
Lopez, JI	1
Holdridge, A	1
Mendizabal, JE	1
Fountain, EM	1
Dhurandhar, A	1
Derry, CJ	2
Derry, S	2
Moore, RA	2
Jayawardena, S	2
Leyva, R	1
Kellstein, D	1
Andrés-del Olmo, B	1
Demelo-Rodríguez, P	1
Muñoz Delgado, C	1
Sanz Sanz, FJ	1
Faasse, K	2
Martin, LR	1
Grey, A	2
Gamble, G	1
Petrie, KJ	2
Bohio, R	1
Brohi, ZP	1
Bohio, F	1
Colgan, SL	1
Pereira, JA	1
Hocevar, S	1
Kennedy, SA	1
Darden, PM	1
Reigart, JR	1
Konrad, B	1
Prate, K	1
Brannasch, K	1
Ettrich, U	1
Manzano, S	1
Doyon-Trottier, E	1
Gertsch, JH	1
Lipman, GS	1
Holck, PS	1
Merritt, A	1
Mulcahy, A	1
Fisher, RS	1
Basnyat, B	1
Allison, E	1
Hanzelka, K	1
Hazan, A	1
Meyers, Z	1
Odegaard, J	1
Pook, B	1
Thompson, M	1
Slomovic, B	1
Wahlberg, H	1
Wilshaw, V	1
Weiss, EA	1
Zafren, K	1
Wark, JD	1
Bensen, W	1
Recknor, C	1
Ryabitseva, O	1
Chiodo, J	1
Mesenbrink, P	1
de Villiers, TJ	1
Zafonte, R	1
Kay, E	1
Ben-Shoshan, M	1
Wenzel, RP	1
Thomas, SH	1
Grebe, W	1
Ionescu, E	1
Gold, MS	1
Liu, JM	1
Frank, WO	1
Leung, M	1
Hollander, Y	1
Brown, GR	1
Mao-Draayer, Y	1
Bingham, P	1
Roth, LS	1
Río, J	1
Nos, C	1
Bonaventura, I	1
Arroyo, R	1
Genis, D	1
Sureda, B	1
Ara, JR	1
Brieva, L	1
Martín, J	1
Saiz, A	1
Sánchez López, F	1
Prieto, JM	1
Roquer, J	1
Dorado, JF	1
Montalban, X	1
Annequin, D	1
Carbajal, R	1
Hoito, K	1
Hämäläinen, M	1
Sádaba, B	1
Campanero, MA	1
Muñoz-Juarez, MJ	1
Gil-Aldea, I	1
García-Quetglas, E	1
Esteras, A	1
Azanza, JR	1
Huntoon, MA	1
Watson, JC	1
Dooley, JM	1
Gordon, KE	1
Wood, EP	1
Brna, PM	1
MacSween, J	1
Fraser, A	1
Venâncio, Rde A	1
Alencar, FG	1
Zamperini, C	1
Diamond, S	1
Sharma, SK	1
Burtscher, M	1
Likar, R	1
Nachbauer, W	1
Schaffert, W	1
Philadelphy, M	1
Broome, JR	1
Stoneham, MD	1
Beeley, JM	1
Milledge, JS	1
Hughes, AS	1
van Gerven, JM	1
Schoemaker, RC	1
Jacobs, LD	1
Reints, A	1
Ouwersloot-van der Meij, MJ	1
Hoedemaker, HG	1
Cohen, AF	1
Symon, DN	1
Pisani, E	1
Fattorello, C	1
Leotta, MR	1
Marcello, O	1
Zuliani, C	1
Olson, NZ	1
Otero, AM	1
Marrero, I	1
Tirado, S	1
Cooper, S	1
Doyle, G	1
Sunshine, A	1
Evers, S	1
Pothmann, R	1
Uberall, M	1
Naumann, E	1
Gerber, WD	1
Kolar, KR	1
Fisher, W	1
Gordon, V	1
Reess, J	1
Haas, J	1
Gabriel, K	1
Fuhlrott, A	1
Fiola, M	1
Dostál, C	1
Pavelka, K	1
Lewit, K	1
Finch, WR	1
Strottman, MP	1
Ryan, RE	1
Scherber, A	1
Nicastro, NJ	1
Schachtel, BP	1
Thoden, WR	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial[NCT03951649]	Phase 4	62 participants (Actual)	Interventional	2020-02-10	Completed
Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain: Study I[NCT01098747]	Phase 3	335 participants (Actual)	Interventional	2010-04-30	Completed
Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Episodic Tension-Type Headache[NCT01077973]	Phase 3	200 participants (Actual)	Interventional	2010-03-31	Completed
Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain[NCT01216163]	Phase 3	218 participants (Actual)	Interventional	2010-10-31	Completed
Ibuprofen Sodium Tension Headache Study[NCT01362491]	Phase 3	226 participants (Actual)	Interventional	2011-06-30	Completed
Evaluation Of The Antipyretic Efficacy Of Ibuprofen Sodium Tablets In Subjects With An Uncomplicated Acute Infection[NCT01035346]	Phase 3	16 participants (Actual)	Interventional	2010-01-31	Terminated
Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen[NCT01522326]		300 participants (Anticipated)	Interventional	2012-03-01	Completed
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a[NCT03424733]	Phase 4	50 participants (Anticipated)	Interventional	2017-09-25	Recruiting
Double-blind, Prospective Comparison of Medications Used in Trigger Point Injections - Ketorolac, Lidocaine, or Dexamethasone[NCT03028012]	Phase 4	10 participants (Actual)	Interventional	2017-05-02	Terminated (stopped due to Poor enrollment.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	days (Median)
Occipital Nerve Block	6
Oral Acetaminophen/Caffeine Group	1

Intervention	Participants (Count of Participants)
Occipital Nerve Block	9
Oral Acetaminophen/Caffeine Group	4

Intervention	Participants (Count of Participants)
Occipital Nerve Block	7
Oral Acetaminophen/Caffeine Group	2

Intervention	Participants (Count of Participants)
Occipital Nerve Block	0
Oral Acetaminophen/Caffeine Group	2

Intervention	Participants (Count of Participants)
Occipital Nerve Block	0
Oral Acetaminophen/Caffeine Group	0

Intervention	Participants (Count of Participants)
Occipital Nerve Block	9
Oral Acetaminophen/Caffeine Group	14

Intervention	Participants (Count of Participants)
Occipital Nerve Block	4
Oral Acetaminophen/Caffeine Group	2

Emergency department for treatment of headache since treatment asked at 28 day follow up (NCT03951649)
Timeframe: 28 days

Number of Participants With Need for Second Line Treatment

Number of Participants With Response to Occipital Nerve Block in Pregnancy

Intervention	Participants (Count of Participants)
Occipital Nerve Block	5
Oral Acetaminophen/Caffeine Group	1

Intervention	Participants (Count of Participants)
Occipital Nerve Block	5
Oral Acetaminophen/Caffeine Group	5

Based on guidelines from the International Headache Society the primary outcome is the portion of women who experience resolution of headache or improvement of headache to mild range (VRS ≤ 3) at 2 hours following treatment with Occipital nerve block as compared to acetaminophen/caffeine cocktail. (NCT03951649)
Timeframe: 60-300 min

Response to Cross Over Treatment at 60 Min

Intervention	Participants (Count of Participants)
Occipital Nerve Block	20
Oral Acetaminophen/Caffeine Group	16

"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 60 min

Response to Second Line Treatment at 60 Min

Intervention	score on a scale (Median)
Occipital Nerve Block	6
Oral Acetaminophen/Caffeine Group	3

Response to Treatment Within 2 Hours

Intervention	score on a scale (Median)
Occipital Nerve Block	6
Oral Acetaminophen/Caffeine Group	4

Participant Global Evaluation of Study Medication

Intervention	score on a scale (Median)
Occipital Nerve Block	6.0
Oral Acetaminophen/Caffeine Group	6.5

Participant global evaluation of study medication was performed at the 8-hour time point or immediately before taking the rescue medication. It was scored on a 6-point categorical scale where 0 = Very poor, 1 = Poor, 2 = Fair, 3 = Good, 4 = Very Good, and 5 = Excellent. (NCT01098747)
Timeframe: 8 hours

Time to Confirmed First Perceptible Relief

Intervention	Units on a scale (Mean)
Placebo	1.1
Ibuprofen Sodium	3.8
Ibuprofen (Advil + Motrin IB)	3.7

Participants evaluated the time to first perceptible relief by stopping a stopwatch labeled 'first perceptible relief' at the moment they first began to experience any relief. Stopwatch was active up to 8 hours after dosing or until stopped by the participant, or rescue medication was administered. The first perceptible relief was considered confirmed if the participant also stopped the second stopwatch indicating meaningful relief. (NCT01098747)
Timeframe: 0 to 8 hours

Time to Onset of Meaningful Relief

Intervention	Minutes (Median)
Placebo	NA
Ibuprofen Sodium	16.4
Ibuprofen (Advil + Motrin IB)	25.7

Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment they first began to experience meaningful relief. Stopwatch was active up to 8 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01098747)
Timeframe: 0 to 8 hours

Time to Treatment Failure

Intervention	Minutes (Median)
Placebo	NA
Ibuprofen Sodium	42.4
Ibuprofen (Advil + Motrin IB)	55.3

Median time of dropping out of the participants from the study due to lack of efficacy or rescue medication, whichever came first. (NCT01098747)
Timeframe: 0 to 8 hours

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-8 Hours (SPRID 0-8)

Intervention	Hours (Median)
Placebo	1.7
Ibuprofen Sodium	NA
Ibuprofen (Advil + Motrin IB)	NA

SPRID: time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 8 hours. SPRID 0-8 score range: -8 (worst) to 56 (best). PRID: sum of Pain intensity differences (PID) and pain relief rating (PRR) at each time point. PRID score range: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (pain severity score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). PID score range: -1(worst) to 3 (best). PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01098747)
Timeframe: 0 to 8 hours

Cumulative Percentage of Participants With Complete Relief

Intervention	Units on a scale (Mean)
Placebo	5.4
Ibuprofen Sodium	29.8

Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

Cumulative Percentage of Participants With Confirmed First Perceptible Relief

Intervention	Percentage of participants (Number)
	0.25 hours	0.5 hours	1 hour	1.5 hours	2 hours	3 hours	4 hours	5 hours	6 hours	7 hours	8 hours
Ibuprofen (Advil + Motrin IB)	0.0	3.5	20.8	32.4	43.9	54.9	61.8	63.0	63.6	64.2	64.2
Ibuprofen Sodium	0.0	6.3	27.4	41.1	48.4	52.6	54.7	54.7	54.7	54.7	54.7
Placebo	0.0	0.0	0.0	0.0	0.0	0.0	6.3	6.3	6.3	6.3	6.3

Percentage of participants with first perceptible relief was evaluated by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief. Stopwatch was active up to 8 hours after dosing or until stopped by the participant, or rescue medication was administered. The first perceptible relief was considered confirmed if the participant also stopped the second stopwatch indicating meaningful relief. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

Cumulative Percentage of Participants With Meaningful Relief

Intervention	Percentage of participants (Number)
	0.25 hours	0.5 hours	1 hour	1.5 hours	2 hours	3 hours	4 hours	5 hours	6 hours	7 hours	8 hours
Ibuprofen (Advil + Motrin IB)	12.1	60.7	84.4	87.3	87.9	88.4	88.4	88.4	88.4	88.4	88.4
Ibuprofen Sodium	26.3	84.2	94.7	95.8	95.8	95.8	95.8	95.8	95.8	95.8	95.8
Placebo	6.3	14.6	20.8	22.9	22.9	22.9	22.9	22.9	22.9	22.9	22.9

Percentage of participants with meaningful relief evaluated by stopping the stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. Stopwatch was active up to 8 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

Cumulative Percentage of Participants With Treatment Failure

Intervention	Percentage of participants (Number)
	0.25 hours	0.5 hours	1 hour	1.5 hours	2 hours	3 hours	4 hours	5 hours	6 hours	7 hours	8 hours
Ibuprofen (Advil + Motrin IB)	0.6	16.8	52.6	69.9	79.8	86.7	87.9	87.9	87.9	87.9	88.4
Ibuprofen Sodium	1.1	28.4	73.7	87.4	91.6	94.7	94.7	94.7	94.7	95.8	95.8
Placebo	0.0	4.2	12.5	14.6	18.8	20.8	20.8	20.8	20.8	20.8	22.9

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

Pain Intensity Difference (PID)

Intervention	Percentage of participants (Number)
	0.25 hours	0.5 hours	1 hour	1.5 hours	2 hours	3 hours	4 hours	5 hours	6 hours	7 hours	8 hours
Ibuprofen (Advil + Motrin IB)	0.0	0.0	0.0	2.3	5.8	8.1	8.1	10.4	12.1	16.2	20.2
Ibuprofen Sodium	0.0	0.0	0.0	1.1	2.1	4.2	9.5	10.5	13.7	20.0	26.3
Placebo	0.0	0.0	0.0	25.0	54.2	70.8	70.8	70.8	72.9	77.1	79.2

PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [none] to 3 [severe]) from the baseline score (Baseline pain severity score range 2 [moderate] to 3 [severe]). Total possible score range for PID: -1 (worst) to 3 (best). (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

Pain Relief Rating (PRR)

Intervention	Units on a scale (Mean)
	0.25 hours	0.5 hours	1 hour	1.5 hour	2 hours	3 hours	4 hours	5 hours	6 hours	7 hours	8 hours
Ibuprofen (Advil + Motrin IB)	0.1	0.6	1.3	1.5	1.7	1.7	1.7	1.6	1.5	1.2	1.1
Ibuprofen Sodium	0.3	1.0	1.5	1.7	1.8	1.6	1.5	1.4	1.2	0.9	0.8
Placebo	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	-0.0	-0.0	-0.0

PRR was evaluated at different time points during the study up to 8 hours after taking the study medication, and immediately before rescue medication was taken (if necessary). PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

Sum of Pain Relief Rating and Pain Intensity Difference (PRID)

Intervention	Units on a scale (Mean)
	0.25 hours	0.5 hours	1 hour	1.5 hours	2 hours	3 hours	4 hours	5 hours	6 hours	7 hours	8 hours
Ibuprofen (Advil + Motrin IB)	0.5	1.5	2.5	2.8	3.0	3.0	3.0	2.8	2.6	2.3	2.2
Ibuprofen Sodium	0.7	2.0	2.9	3.1	3.1	2.9	2.8	2.6	2.3	1.9	1.7
Placebo	0.4	0.5	0.6	0.7	0.7	0.7	0.8	0.7	0.7	0.5	0.5

PRID was sum of PID and PRR at each post-dosing time point. The overall possible score range, for PRID was -1 (worst) to 7 (best). PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [none] to 3 [severe]) from the baseline score (Baseline pain severity score range 2 [moderate] to 3 [severe]). Total possible score range for PID: -1 (worst) to 3 (best). PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief). (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

Time-weighted Sum of Pain Intensity Difference (SPID)

Intervention	Units on a scale (Mean)
	0.25 hours	0.5 hours	1 hour	1.5 hours	2 hours	3 hours	4 hours	5 hours	6 hours	7 hours	8 hours
Ibuprofen (Advil + Motrin IB)	0.6	2.1	3.8	4.3	4.7	4.7	4.8	4.4	4.1	3.5	3.2
Ibuprofen Sodium	1.1	3.0	4.4	4.8	4.9	4.5	4.3	4.0	3.5	2.9	2.6
Placebo	0.4	0.6	0.7	0.7	0.8	0.7	0.9	0.8	0.6	0.5	0.5

SPID: time-weighted sum of PID over 2, 3, 6 and 8 hours. SPID scores range was -2 (worst) to 6 (best) for SPID 0-2, -3 (worst) to 9 (best) for SPID 0-3, -6 (worst) to 18 (best) for SPID 0-6, -8 (worst) to 24 (best) for SPID 0-8. PID: baseline pain severity score minus pain severity score at a given time point (pain severity score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1(worst) to 3 (best). (NCT01098747)
Timeframe: 0-2, 0-3, 0-6, 0-8 hours

Time-weighted Sum of Pain Relief Rating (TOTPAR)

Intervention	Units on a scale (Mean)
	SPID 0-2	SPID 0-3	SPID 0-6	SPID 0-8
Ibuprofen (Advil + Motrin IB)	2.4	4.1	8.9	11.1
Ibuprofen Sodium	2.8	4.4	8.5	10.2
Placebo	0.1	0.1	0.2	0.1

TOTPAR: time-weighted sum of PRR scores over 2, 3, 6 and 8 hours. TOTPAR score range was 0 (worst) to 8 (best) for TOTPAR 0-2, 0 (worst) to 12 (best) for TOTPAR 0-3, 0 (worst) to 24 (best) for TOTPAR 0-6, 0 (worst) to 32 (best) for TOTPAR 0-8. PRR was evaluated at different time points during the study up to 8 hours, and immediately after taking rescue medication (if necessary). PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01098747)
Timeframe: 0-2, 0-3, 0-6, 0-8 hours

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)

Intervention	Units on a scale (Mean)
	TOTPAR 0-2	TOTPAR 0-3	TOTPAR 0-6	TOTPAR 0-8
Ibuprofen (Advil + Motrin IB)	4.6	7.6	16.1	20.6
Ibuprofen Sodium	5.2	8.1	15.9	19.5
Placebo	1.3	2.0	4.2	5.2

SPRID: time-weighted sum of PRID over 2, 3, 6 and 8 hours. SPRID score range:-2 (worst) to 14(best) for SPRID 0-2, -3(worst) to 21(best) for SPRID 0-3, -6(worst) to 42(best) for SPRID 0-6, -8(worst) to 56(best) for SPRID 0-8. PRID:sum of PID and PRR at each time point. Total score range for PRID: -1=worst to 7=best. PID:baseline pain severity score minus pain severity score at given time(score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1(worst) to 3(best), PRR: scored on 5-point pain relief rating scale(0=No relief to 4=Complete relief). (NCT01098747)
Timeframe: 0-2, 0-3, 0-6, 0-8 hours

Time to Confirmed First Perceptible Relief

Intervention	Units on a scale (Mean)
	SPRID 0-2	SPRID 0-3	SPRID 0-6	SPRID 0-8
Ibuprofen (Advil + Motrin IB)	7.0	11.8	25.0	31.7
Ibuprofen Sodium	8.0	12.6	24.3	29.8
Placebo	1.3	2.1	4.4	5.4

"Participants evaluated the time to first perceptible relief by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered. First perceptible relief was considered confirmed by meaningful relief if the participant achieved both first perceptible and meaningful relief by either depressing the second stopwatch or by indicating that his/her first perceptible relief was also meaningful." (NCT01077973)
Timeframe: 0 to 3 hours

Time to Onset of Meaningful Relief for Ibuprofen Sodium Versus Ibuprofen (Motrin IB) Tablet

Intervention	Minutes (Median)
Placebo	42.3
Ibuprofen Sodium	41.7
Ibuprofen (Motrin IB)	43.8

"Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated meaningful relief at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered." (NCT01077973)
Timeframe: 0 to 3 hours

Time to Onset of Meaningful Relief: Remaining Comparisons

Intervention	Minutes (Median)
Ibuprofen Sodium	50.3
Ibuprofen (Motrin IB)	55.5

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet

Intervention	Minutes (Median)
Placebo	48.2
Ibuprofen Sodium	50.3
Ibuprofen (Motrin IB)	55.5

SPRID:time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 3 hours. SPRID score range:-3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of pain intensity differences (PID) and pain relief rating(PRR) at each time point. PRID score range: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3 (best). PRR:assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01077973)
Timeframe: 0 to 3 hours

Cumulative Percentage of Participants With Complete Relief

Intervention	Units on a scale (Mean)
Placebo	11.2
Ibuprofen Sodium	10.8

Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01077973)
Timeframe: 1, 2, 3 hours

Cumulative Percentage of Participants With Confirmed First Perceptible Relief

Intervention	Percentage of participants (Number)
	1 hour	2 hours	3 hours
Ibuprofen (Motrin IB)	1.3	15.0	35.0
Ibuprofen Sodium	6.3	21.5	40.5
Placebo	2.4	17.1	41.5

"Percentage of participants with first perceptible relief evaluated by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered. First perceptible relief was considered confirmed by meaningful relief if the participant achieved both first perceptible and meaningful relief by either depressing the second stopwatch or by indicating that his/her first perceptible relief was also meaningful." (NCT01077973)
Timeframe: 0.5, 1, 2, 3 hours

Cumulative Percentage of Participants With Meaningful Relief

Intervention	Percentage of participants (Number)
	0.5 hours	1 hour	2 hours	3 hours
Ibuprofen (Motrin IB)	28.8	72.5	82.5	82.5
Ibuprofen Sodium	30.4	67.1	81.0	81.0
Placebo	24.4	80.5	85.4	85.4

"Percentage of participants with meaningful relief evaluated by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated meaningful relief at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered." (NCT01077973)
Timeframe: 0.5, 1, 2, 3 hours

Pain Intensity Difference (PID)

Intervention	Percentage of participants (Number)
	0.5 hours	1 hour	2 hours	3 hours
Ibuprofen (Motrin IB)	10.0	60.0	81.3	82.5
Ibuprofen Sodium	17.7	58.2	79.7	81.0
Placebo	14.6	65.9	85.4	85.4

PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)]. Total possible score range for PID: -1 (worst) to 3 (best). (NCT01077973)
Timeframe: 1, 2, 3 hours

Pain Relief Rating (PRR)

Intervention	Units on a scale (Mean)
	1 hour	2 hours	3 hours
Ibuprofen (Motrin IB)	0.8	1.2	1.4
Ibuprofen Sodium	0.9	1.3	1.5
Placebo	0.9	1.3	1.5

PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01077973)
Timeframe: 1, 2, 3 hours

Sum of Pain Relief Rating and Pain Intensity Difference (PRID)

Intervention	Units on a scale (Mean)
	1 hour	2 hours	3 hours
Ibuprofen (Motrin IB)	1.6	2.4	2.7
Ibuprofen Sodium	1.9	2.5	2.8
Placebo	1.9	2.6	3.0

PRID was sum of PID and PRR at each post-dosing time point. The overall possible score range, for PRID was -1 (worst) to 7 (best). PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)]. Total possible score range for PID: -1 (worst) to 3 (best). PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief). (NCT01077973)
Timeframe: 1, 2, 3 hours

Time-weighted Sum of Pain Intensity Difference (SPID)

Intervention	Units on a scale (Mean)
	1 hour	2 hours	3 hours
Ibuprofen (Motrin IB)	2.4	3.6	4.1
Ibuprofen Sodium	2.8	3.7	4.3
Placebo	2.8	3.9	4.5

SPID: time-weighted sum of PID over 2 and 3 hours. SPID score range was -2(worst) to 6 (best) for SPID 0-2 and -3 (worst) to 9 (best) for SPID 0-3. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3 (best). (NCT01077973)
Timeframe: 0 to 2, 0 to 3 hours

Time-weighted Sum of Pain Relief Rating (TOTPAR)

Intervention	Units on a scale (Mean)
	SPID 0-2	SPID 0-3
Ibuprofen (Motrin IB)	2.0	3.4
Ibuprofen Sodium	2.2	3.6
Placebo	2.2	3.8

TOTPAR: time-weighted sum of PRR over 2 and 3 hours. TOTPAR score range was 0 (worst) to 8 (best) for TOTPAR 0-2 and 0 (worst) to 12 (best) for TOTPAR 0-3. PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01077973)
Timeframe: 0 to 2, 0 to 3 hours

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)

Intervention	Units on a scale (Mean)
	TOTPAR 0-2	TOTPAR 0-3
Ibuprofen (Motrin IB)	4.1	6.8
Ibuprofen Sodium	4.4	7.2
Placebo	4.5	7.5

SPRID: time-weighted sum of PRID over 2 and 3 hours. SPRID score range was -2(worst) to 14(best) for SPRID 0-2 and -3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of PID and PRR at each time point. Total score range for PRID: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3(best), PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01077973)
Timeframe: 0 to 2, 0 to 3 hours

Participant Global Evaluation of Study Medication

Intervention	Units on a scale (Mean)
	SPRID 0-2	SPRID 0-3
Ibuprofen (Motrin IB)	6.1	10.2
Ibuprofen Sodium	6.5	10.8
Placebo	6.7	11.2

Participant global evaluation of study medication was performed at the 6-hour time point or immediately before taking the rescue medication. It was scored on a 6-point categorical scale where 0 = Very poor, 1 = Poor, 2 = Fair, 3 = Good, 4 = Very Good, and 5 = Excellent. (NCT01216163)
Timeframe: 6 hours

Time to Confirmed First Perceptible Relief

Intervention	units on a scale (Mean)
Placebo	0.9
Ibuprofen Sodium	3.5
Acetaminophen	3.0

Participants evaluated the time to first perceptible relief by stopping a stopwatch labeled 'first perceptible relief' at the moment they first began to experience any relief. Stopwatch was active up to 6 hours after dosing or until stopped by the participant, or rescue medication was administered. The first perceptible relief was considered confirmed if the participant also stopped the second stopwatch indicating meaningful relief. (NCT01216163)
Timeframe: 0 to 6 hours

Time to Onset of Meaningful Relief

Intervention	minutes (Median)
Placebo	NA
Ibuprofen Sodium	16.0
Acetaminophen	23.7

Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment they first began to experience meaningful relief. Stopwatch was active up to 6 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01216163)
Timeframe: 0 to 6 hours

Time to Treatment Failure

Intervention	minutes (Median)
Placebo	NA
Ibuprofen Sodium	58.0
Acetaminophen	53.4

Median time of dropping out of the participants from the study due to lack of efficacy or use of rescue medication, whichever comes first. (NCT01216163)
Timeframe: 0 to 6 hours

Time-weighted Sum of Pain Relief Rating With Pain Intensity Difference From 0 to 6 Hours (SPRID 0-6)

Intervention	hours (Median)
Placebo	1.6
Ibuprofen Sodium	NA
Acetaminophen	NA

SPRID: time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 6 hours. Score range: -6(worst) to 42(best) for SPRID 0-6. PRID: sum of pain intensity difference (PID) and pain relief rating (PRR) at each time point. Score range for PRID: -1(worst) to 7(best). PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1 (worst) to 3 (best). PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01216163)
Timeframe: 0 to 6 hours

Cumulative Percentage of Participants With Complete Relief

Intervention	units on a scale (Mean)
Placebo	2.8
Ibuprofen Sodium	20.0
Acetaminophen	17.1

Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

Cumulative Percentage of Participants With Confirmed First Perceptible Relief

Percentage of participants with first perceptible relief evaluated by stopping the stopwatch labeled 'first perceptible relief' at the moment participant first began to experience any relief. First perceptible relief was considered confirmed if the participant also stopped the second stopwatch indicating meaningful relief. Stopwatch was active up to 6 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

Cumulative Percentage of Participants With Meaningful Relief

Percentage of participants with meaningful relief evaluated by stopping the stopwatch labeled 'meaningful relief' at the moment participant first began to experience meaningful relief. Stopwatch was active up to 6 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

Cumulative Percentage of Participants With Treatment Failure

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

Pain Intensity Difference (PID)

PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [none] to 3 [severe]) from the baseline score (Baseline pain severity score range 2 [moderate] to 3 [severe]). Total possible score range for PID: -1 (worst) to 3 (best). (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

Pain Relief Rating (PRR)

PRR was evaluated at different time points during the study up to 6 hours after taking the study medication, and immediately before rescue medication was taken (if necessary). PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

Sum of Pain Relief Rating and Pain Intensity Difference (PRID)

PRID was sum of PID and PRR at each post-dosing time point. The overall possible score range, for PRID was -1 (worst) to 7 (best). PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [none] to 3 [severe]) from the baseline score (Baseline pain severity score range 2 [moderate] to 3 [severe]). Total possible score range for PID: -1 (worst) to 3 (best). PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief). (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

Time-weighted Sum of Pain Intensity Difference (SPID)

SPID: time-weighted sum of PID over 2, 3 and 6 hours. Total score range: -2 (worst) to 6 (best) for SPID 0-2, -3 (worst) to 9 (best) for SPID 0-3, and -6 (worst) to 18 (best) for SPID 0-6. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1 (worst) to 3 (best). (NCT01216163)
Timeframe: 0 to 2, 0 to 3, 0 to 6 hours

Time-weighted Sum of Pain Relief Rating (TOTPAR)

TOTPAR: time-weighted sum of PRR over 2, 3, and 6 hours. Total score range: 0 (worst) to 8 (best) for TOTPAR 0-2, 0 (worst) to 12 (best) for TOTPAR 0-3, and 0 (worst) to 24 (best) for TOTPAR 0-6. PRR was evaluated at different time points during the study up to 6 hours, and immediately after taking rescue medication (if necessary). PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01216163)
Timeframe: 0 to 2, 0 to 3, 0 to 6 hours

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)

SPRID: time-weighted sum of PRID over 2 and 3 hours. Total score range: -2 (worst) to 14 (best) for SPRID 0-2, and -3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of PID and PRR at each time point. Total score range for PRID: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1 (worst) to 3 (best). PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01216163)
Timeframe: 0 to 2, 0 to 3 hours

Cumulative Percentage of Participants With Treatment Failure

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication. (NCT01362491)
Timeframe: 1, 2, 3 hours post-dose

Time to Confirmed First Perceptible Relief

Time to Onset of Meaningful Relief for Ibuprofen Sodium Versus Ibuprofen (Motrin IB) Tablet

Time to Onset of Meaningful Relief: Remaining Comparisons

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet

Cumulative Percentage of Participants With Complete Relief

Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief (NCT01362491)
Timeframe: 1, 2, & 3 hours post-dose

Cumulative Percentage of Participants With First Perceptible Relief

Cumulative Percentage of Participants With Meaningful Relief

Pain Intensity Difference (PID)

Pain Relief Rating (PRR)

PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01362491)
Timeframe: 1, 2 & 3 hours post-dose

Sum of Pain Relief Rating and Pain Intensity Difference (PRID)

PRID was sum of PID and PRR at each post-dosing time point. The overall possible score range, for PRID was -1 (worst) to 7 (best). PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)]. Total possible score range for PID: -1 (worst) to 3 (best). PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief). (NCT01362491)
Timeframe: 1, 2 & 3 hours post-dose

Time-weighted Sum of Pain Intensity Difference (SPID)

Time-weighted Sum of Pain Relief Rating (TOTPAR)

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)

Global Assessment of Study Medication as an Antipyretic

Global assessment of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent. (NCT01035346)
Timeframe: 8 hours

Rating of Study Medication Relative to Usual Medication

Rating of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent. (NCT01035346)
Timeframe: 8 hours

Time to Treatment Failure

Median time of dropping out of the participants from the study due to lack of efficacy or use of rescue medication, whichever comes first. (NCT01035346)
Timeframe: 0 to 8 hours

Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)

STEMPD 0-6 was defined as time-weighted sum of temperature differences over 6 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature. (NCT01035346)
Timeframe: 0 to 6 hours

Change From Baseline in Temperature at Hours 0.25, 0.5, 1, 2, 4, 6 and 8

Change from baseline in temperature was calculated as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature. (NCT01035346)
Timeframe: Baseline, 0.25, 0.5, 1, 2, 4, 6, 8 hours

Cumulative Percentage of Participants With Treatment Failure

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication. (NCT01035346)
Timeframe: 0.25, 0.5, 1, 2, 4, 6, 8 hours

Time-weighted Sum of The Temperature Differences From Baseline Through Hour 4 and Hour 8 (STEMPD 0-4 and STEMPD 0-8)

STEMPD 0-4 and STEMPD 0-8 were defined as the time-weighted sum of temperature differences over 4 hours and 8 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature. (NCT01035346)
Timeframe: 0 to 4, 0 to 8 hours

Number of Participants With a Responder Rate Greater Than 50% on the Numeric Rating Pain Scale (NRS) Improvement

Participants in this study underwent TPIs by the following method. The needle was inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. This was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain, one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Post Injections Up to Three Months

Brief Pain Inventory (BPI) - Modified

The BPI was evaluated on a scale from 0-10. Zero would mean no interference and 10 would be calculated at complete interferences. We used a 7-point questionnaire about pain. All scores were calculated at baseline and three months. (NCT03028012)
Timeframe: Baseline and Three Months

Numeric Rating Pain Scale (NRS) at Baseline and Three Months.

TPI were treated with a needle inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. Such was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain,one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Injection and Three Month Post Injection(s)

Intervention	percentage of participants (Number)
	0.25 hours	0.5 hours	1 hours	1.5 hours	2 hours	3 hours	4 hours	5 hours	6 hours
Acetaminophen	1.2	4.7	15.3	24.7	29.4	32.9	35.3	35.3	35.3
Ibuprofen Sodium	0.0	6.8	23.9	29.5	36.4	42.0	45.5	45.5	46.6
Placebo	0.0	0.0	0.0	0.0	4.4	4.4	6.7	8.9	8.9

Intervention	score on a scale (Number)
	Participant Number #3 at Baseline	Participant Number #3 at 3 Months	Participant Number #8 at Baseline	Participant #8 at 3 Months
Ketorolac	8	3	5	3

Intervention	score on a scale (Number)
	Participant Number 3 at Baseline	Participant Number 3 at 3 Months	Participant Number 8 at Baseline	Participant Number 8 at 3 Months
Ketorolac	8	3	5	3

Article	Year
Efficacy of ibuprofen on prevention of high altitude headache: A systematic review and meta-analysis. PloS one, 2017, Volume: 12, Issue:6 Topics: Altitude; Anti-Inflammatory Agents, Non-Steroidal; Databases, Factual; Headache; Humans; Ibuprofen;	2017
Caffeine in the management of patients with headache. The journal of headache and pain, 2017, Oct-24, Volume: 18, Issue:1 Topics: Abdominal Pain; Acetaminophen; Adult; Analgesics; Aspirin; Caffeine; Central Nervous System Stimulan	2017
[Headache in children and adolescents]. Ugeskrift for laeger, 2018, Feb-12, Volume: 180, Issue:7 Topics: Acetaminophen; Acute Pain; Adolescent; Analgesics, Non-Narcotic; Child; Diagnosis, Differential; Eme	2018
Update on the pathophysiology and treatment of rhinogenic headache: focus on the ibuprofen/pseudoephedrine combination. Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2019, Volume: 39, Issue:1 Topics: Drug Administration Schedule; Drug Therapy, Combination; Headache; Humans; Ibuprofen; Placebo Effect	2019
Altitude headache. Current pain and headache reports, 2013, Volume: 17, Issue:12 Topics: Acute Disease; Adaptation, Physiological; Altitude; Altitude Sickness; Anti-Inflammatory Agents; Asp	2013
Caffeine as an analgesic adjuvant for acute pain in adults. The Cochrane database of systematic reviews, 2014, Dec-11, Issue:12 Topics: Acetaminophen; Acute Pain; Adolescent; Adult; Aged; Analgesics; Caffeine; Chemotherapy, Adjuvant; Di	2014
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgraduate medicine, 2015, Volume: 127, Issue:1 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me	2015
[Physiotherapy in patients with chronic pain]. MMW Fortschritte der Medizin, 2010, Jan-14, Volume: 152, Issue:1-2 Topics: Analgesics, Non-Narcotic; Back Pain; Chronic Disease; Combined Modality Therapy; Exercise Movement T	2010
Myth: Ibuprofen is superior to acetaminophen for the treatment of benign headaches in children and adults. CJEM, 2010, Volume: 12, Issue:3 Topics: Acetaminophen; Adolescent; Adult; Altitude Sickness; Analgesics, Non-Narcotic; Child; Headache; Huma	2010
Caffeine as an analgesic adjuvant for acute pain in adults. The Cochrane database of systematic reviews, 2012, Mar-14, Issue:3 Topics: Acetaminophen; Acute Pain; Adult; Analgesics; Caffeine; Chemotherapy, Adjuvant; Female; Headache; Hu	2012
Two teenagers with headaches. Pediatric case reviews (Print), 2003, Volume: 3, Issue:3 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Female; Headache; Huma	2003
[Diagnosis and care of repeating headache in children]. Duodecim; laaketieteellinen aikakauskirja, 2005, Volume: 121, Issue:6 Topics: Acetaminophen; Age Factors; Child; Child, Preschool; Chronic Disease; Female; Finland; Headache; Hum	2005
[Treatment of idiopathic headache in childhood - recommendations of the German Migraine and Headache Society (DMKG)]. Schmerz (Berlin, Germany), 2002, Volume: 16, Issue:1 Topics: Acetaminophen; Adrenergic beta-Antagonists; Age Factors; Analgesics, Non-Narcotic; Biofeedback, Psyc	2002
"Nurse, my head hurts": a review of childhood headaches. The Journal of school nursing : the official publication of the National Association of School Nurses, 2001, Volume: 17, Issue:3 Topics: Acetaminophen; Adolescent; Age Factors; Analgesics, Non-Narcotic; Child; Child, Preschool; Emergenci	2001
[Therapy of headache with analgesics]. Zeitschrift fur arztliche Fortbildung, 1991, Jan-25, Volume: 85, Issue:1-2 Topics: Acetaminophen; Analgesics; Aspirin; Headache; Humans; Ibuprofen; Pyrazoles; Pyrazolones	1991

Article	Year
Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial. The American journal of emergency medicine, 2022, Volume: 55 Topics: Double-Blind Method; Emergency Service, Hospital; Headache; Humans; Ibuprofen; Migraine Disorders; P	2022
Additive Value of Intranasal Fentanyl on Ibuprofen for Pain Management of Children With Moderate to Severe Headaches: A Randomized Controlled Trial. The Journal of emergency medicine, 2023, Volume: 65, Issue:2 Topics: Adolescent; Analgesics, Opioid; Child; Double-Blind Method; Fentanyl; Headache; Humans; Ibuprofen; P	2023
Effects of preemptive intravenous paracetamol and ibuprofen on headache and myalgia in patients after electroconvulsive therapy: A placebo-controlled, double-blind, randomized clinical trial. Medicine, 2019, Volume: 98, Issue:51 Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Depressive Disorder, Major; Double-Blind Method; Ele	2019
Prospective Double-Blinded Randomized Field-Based Clinical Trial of Metoclopramide and Ibuprofen for the Treatment of High Altitude Headache and Acute Mountain Sickness. Wilderness & environmental medicine, 2020, Volume: 31, Issue:1 Topics: Adult; Altitude Sickness; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Cyclooxygenase Inhib	2020
Indomethacin has no effect on trigeminally provoked parasympathetic output. Cephalalgia : an international journal of headache, 2022, Volume: 42, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Headache; Humans; Ibuprofen; Indometha	2022
A new lipid formulation of low dose ibuprofen shows non-inferiority to high dose standard ibuprofen: the FLARE study (flaring arthralgia relief evaluation in episodic flaring knee pain) - a randomised double-blind study. Osteoarthritis and cartilage, 2017, Volume: 25, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Capsules; Double-Blind	2017
Impact of brand or generic labeling on medication effectiveness and side effects. Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2016, Volume: 35, Issue:2 Topics: Adolescent; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Fema	2016
Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness & environmental medicine, 2010, Volume: 21, Issue:3 Topics: Acetazolamide; Adolescent; Adult; Aged; Altitude Sickness; Anti-Inflammatory Agents, Non-Steroidal;	2010
Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:2 Topics: Acetaminophen; Aged; Arthralgia; Body Temperature; Bone Density Conservation Agents; Diphosphonates;	2012
High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. The Journal of emergency medicine, 2003, Volume: 24, Issue:4 Topics: Acetaminophen; Adult; Altitude Sickness; Analgesics, Opioid; Double-Blind Method; Female; Headache;	2003
A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms. Clinical therapeutics, 2003, Volume: 25, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Drug Administration	2003
Pretreatment with ibuprofen to prevent electroconvulsive therapy-induced headache. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:5 Topics: Adult; Aged; Analgesics, Non-Narcotic; Depressive Disorder; Double-Blind Method; Electroconvulsive T	2003
Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology, 2004, Aug-10, Volume: 63, Issue:3 Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Asthenia; Chills; Double-Blind Method; Drug Administ	2004
A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers. European journal of clinical pharmacology, 2006, Volume: 62, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Algorithms; Analysis of Variance; Anti-Inflammatory Agents,	2006
Caffeine as an adjuvant to ibuprofen in treating childhood headaches. Pediatric neurology, 2007, Volume: 37, Issue:1 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Central Nervous System Stimulants; Ch	2007
Different substances and dry-needling injections in patients with myofascial pain and headaches. Cranio : the journal of craniomandibular practice, 2008, Volume: 26, Issue:2 Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Anesthetics, Local; Anti-Inflammatory Agents; Ant	2008
Ibuprofen versus aspirin and placebo in the treatment of muscle contraction headache. Headache, 1983, Volume: 23, Issue:5 Topics: Adult; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Headache; Humans; Ibuprofen;	1983
Ibuprofen versus sumatriptan for high-altitude headache. Lancet (London, England), 1995, Jul-22, Volume: 346, Issue:8969 Topics: Administration, Oral; Adult; Altitude Sickness; Cross-Over Studies; Double-Blind Method; Female; Hea	1995
High altitude headache: treatment with ibuprofen. Aviation, space, and environmental medicine, 1994, Volume: 65, Issue:1 Topics: Altitude Sickness; Double-Blind Method; Female; Headache; Humans; Ibuprofen; Male; Pain Measurement	1994
Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. British journal of clinical pharmacology, 1996, Volume: 42, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Headache; Humans; Ibuprofen; Ketoprofen; Placebos; Self Med	1996
Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain. Journal of clinical pharmacology, 2001, Volume: 41, Issue:11 Topics: Abdominal Pain; Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory	2001
Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy. Multiple sclerosis (Houndmills, Basingstoke, England), 2002, Volume: 8, Issue:1 Topics: Acetaminophen; Adult; Chills; Female; Fever; Headache; Humans; Ibuprofen; Interferon beta-1a; Interf	2002
[Ibuprofen in the treatment of the cervicocranial syndrome in combination with manipulative therapy]. Fysiatricky a reumatologicky vestnik, 1978, Volume: 56, Issue:5 Topics: Adult; Cervical Vertebrae; Clinical Trials as Topic; Headache; Humans; Ibuprofen; Male; Manipulation	1978
Onset of action of ibuprofen in the treatment of muscle-contraction headache. Headache, 1988, Volume: 28, Issue:7 Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Headache; Humans; Ibuprofen; Muscl	1988

Article	Year
Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects? Drug discoveries & therapeutics, 2021, Nov-21, Volume: 15, Issue:5 Topics: Acetaminophen; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; COVID-19 Vaccines; Fati	2021
Migraine abortive treatment in children and adolescents in Israel. Scientific reports, 2022, 05-06, Volume: 12, Issue:1 Topics: Acetaminophen; Adolescent; Child; Dipyrone; Female; Headache; Humans; Ibuprofen; Israel; Male; Migra	2022
Racial differences in treatment among patients with acute headache evaluated in the emergency department and discharged home. The American journal of emergency medicine, 2022, Volume: 60 Topics: Acetaminophen; Acute Pain; Analgesics; Emergency Service, Hospital; Headache; Healthcare Disparities	2022
Tracing the influence of caffeine on the pharmacokinetic parameters of three headache relieving pharmaceuticals applying synchronous fluorescence spectroscopy. Methods and applications in fluorescence, 2022, Aug-08, Volume: 10, Issue:4 Topics: Caffeine; Headache; Humans; Ibuprofen; Micelles; Spectrometry, Fluorescence	2022
Early analgesic administration and headache presence 7 days post-concussion in children. CJEM, 2022, Volume: 24, Issue:8 Topics: Acetaminophen; Adolescent; Analgesics; Brain Concussion; Canada; Child; Headache; Humans; Ibuprofen;	2022
2022 Taiwan Guidelines for Acute Treatment of Migraine. Acta neurologica Taiwanica, 2022, Jun-30, Volume: 31(2) Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Caffeine; Calcitonin G	2022
Transient tunnel vision and altered consciousness after a single dose of ibuprofen. The Journal of international medical research, 2022, Volume: 50, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Consciousness; Headache; Humans; Ibuprofen; Male; Middle Ag	2022
Social Media Listening and Digital Profiling Study of People With Headache and Migraine: Retrospective Infodemiology Study. Journal of medical Internet research, 2023, 05-05, Volume: 25 Topics: Headache; Humans; Ibuprofen; Infodemiology; Migraine Disorders; Retrospective Studies; Social Media	2023
What do patients' efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry. Cephalalgia : an international journal of headache, 2023, Volume: 43, Issue:5 Topics: Adult; Analgesics, Non-Narcotic; Cross-Sectional Studies; Female; Headache; Humans; Ibuprofen; Middl	2023
Headache medication and the COVID-19 pandemic. The journal of headache and pain, 2020, Apr-25, Volume: 21, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh	2020
Differential actions of indomethacin: clinical relevance in headache. Pain, 2021, 02-01, Volume: 162, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Headache; Humans; Ibuprofen; Indomethacin; Naproxen	2021
Familial thrombocytopenia flare-up following the first dose of mRNA-1273 Covid-19 vaccine. American journal of hematology, 2021, 05-01, Volume: 96, Issue:5 Topics: 2019-nCoV Vaccine mRNA-1273; Adult; Analgesics, Non-Narcotic; Chronic Disease; COVID-19; COVID-19 Va	2021
A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers. Clinical pharmacology in drug development, 2018, Volume: 7, Issue:7 Topics: Administration, Topical; Adult; Area Under Curve; Female; Headache; Healthy Volunteers; Humans; Ibup	2018
[In process]. Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:9 Topics: Adolescent; Adrenergic beta-Antagonists; Age Factors; Analgesics; Behavior Therapy; Child; Flunarizi	2016
Treating Therapy-Resistant Headache After Aneurysmal Subarachnoid Hemorrhage with Acupuncture. Neurocritical care, 2019, Volume: 31, Issue:2 Topics: Acetaminophen; Acupuncture Therapy; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Dipy	2019
IBUPROFEN-INDUCED ASEPTIC MENINGITIS: A CASE REPORT. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 2019, Volume: 37, Issue:3 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Drug Hypersensitivity;	2019
Neuro-Behçet's disease: an unusual cause of headache. Journal of general internal medicine, 2014, Volume: 29, Issue:6 Topics: Anti-Inflammatory Agents; Behcet Syndrome; Diagnosis, Differential; Female; Gait Disorders, Neurolog	2014
[Ibuprofen-induced recurrent aseptic meningitis with good response to corticosteroids]. Medicina clinica, 2016, Feb-05, Volume: 146, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Emergencies; Headache; Human	2016
Utilization of over the counter medication among pregnant women; a cross-sectional study conducted at Isra University Hospital, Hyderabad. JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:1 Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal;	2016
Changing perceptions and efficacy of generic medicines: An intervention study. Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2016, Volume: 35, Issue:11 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Substitution; Drug-Related Side Eff	2016
Headache in children. Journal of the South Carolina Medical Association (1975), 2008, Volume: 104, Issue:6 Topics: Acetaminophen; Adolescent; Age Factors; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child;	2008
[Update on current care guidelines; childhood headache]. Duodecim; laaketieteellinen aikakauskirja, 2010, Volume: 126, Issue:14 Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Headache; Humans; Ibuprofen; Propranolol	2010
Diagnosis and management of sports-related concussion: a 15-year-old athlete with a concussion. JAMA, 2011, Jul-06, Volume: 306, Issue:1 Topics: Accidental Falls; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Athletic Injuries; Brain Conc	2011
Anaphylaxis to ibuprofen in a 12-year-old boy. BMJ case reports, 2013, Jan-14, Volume: 2013 Topics: Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Child; Diagnosis, Differential; Headache; Huma	2013
Acetaminophen preferable to ibuprofen for pretreatment of electroconvulsive therapy-induced headache. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:5 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Electroconvulsive	2004
[Ibuprofen: a febrile rumor]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2005, Volume: 12, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Chickenpox; Child; Child Welfare; Contraindications; Fever;	2005
[Update on current care guidelines. Headache among children]. Duodecim; laaketieteellinen aikakauskirja, 2005, Volume: 121, Issue:4 Topics: Acetaminophen; Analgesics; Child; Child, Preschool; Cohort Studies; Female; Finland; Follow-Up Studi	2005
Intracranial hypotension following motor vehicle accident: an overlooked cause of post-traumatic head and neck pain? Pain practice : the official journal of World Institute of Pain, 2007, Volume: 7, Issue:1 Topics: Accidents, Traffic; Analgesics; Aspirin; Blood Patch, Epidural; Diplopia; Drug Therapy, Combination;	2007
Ibuprofen (Brufen) induced bronchial asthma. The Journal of the Association of Physicians of India, 1984, Volume: 32, Issue:9 Topics: Asthma; Drug Hypersensitivity; Headache; Humans; Ibuprofen	1984
Twelve cases of analgesic headache. Archives of disease in childhood, 1998, Volume: 78, Issue:6 Topics: Acetaminophen; Adolescent; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Codeine; Drug	1998
Recurrence of ibuprofen-induced aseptic meningitis in an otherwise healthy patient. Italian journal of neurological sciences, 1999, Volume: 20, Issue:1 Topics: Aged; Aggression; Anti-Inflammatory Agents, Non-Steroidal; Cerebrospinal Fluid; Diagnosis, Different	1999
Acute adverse reactions to ibuprofen in systemic lupus erythematosus. JAMA, 1979, Jun-15, Volume: 241, Issue:24 Topics: Acute Disease; Adult; Arthritis; Drug Hypersensitivity; Female; Fever; Headache; Humans; Hypotension	1979
Motrin--a new agent for the symptomatic treatment of muscle contraction headache. Headache, 1977, Volume: 16, Issue:6 Topics: Adult; Aged; Headache; Humans; Ibuprofen; Middle Aged; Muscle Contraction; Phenylpropionates	1977
Visual disturbances associated with over-the-counter ibuprofen in three patients. Annals of ophthalmology, 1989, Volume: 21, Issue:12 Topics: Adult; Female; Fluorescein Angiography; Headache; Humans; Ibuprofen; Nonprescription Drugs; Vision D	1989